Researchers from the University of Copenhagen and Insilico Medicine have collaborated to discover new uses for artificial intelligence (AI) within the life science industry. Using the AI method known as ‘deep learning’, researchers are able to sort data sets for gene expression, and determine which molecules can stimulate DNA repair. The goal of the project is to extend healthy human longevity. “Many of the age-related diseases, such as Alzheimer’s disease, Parkinson disease, cardiovascular disease and aging itself are strongly associated with the decline of DNA repair mechanisms,” said Zhu.1

Insilico’s Qingsong Zhu told Biopharma-Reporter that the University would be in charge of testing the molecules. Zhu further explained, “Insilico will make in silico predictions and the University of Copenhagen will validate some of the predictions in vitro and in vivo.”1

The University’s Morten Scheibye-Knudsen has hopes that the research will benefit older populations and increase the limit on human lifespan.

Pearl Pathways’ vision is to improve the clinical research process and deliver new therapeutics and diagnostics to patients sooner. We routinely partner with life science service providers such as academic institutions engaged in human subject trials. Learn more about our services for service providers here.